GlassScriptPhysician profile
Kim C Ford
NPI 1144468398
$2,226.23
in general payments reported to CMS, 2019-2025
15 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $719 · 2023: $418 · 2024: $235 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $485.54 | 2021-2024 | Airsupra |
| Coloplast Corp | $360.96 | 2024-2025 | |
| Novo Nordisk INC | $222.44 | 2021-2022 | |
| Abbvie INC. | $153.86 | 2021-2022 | |
| Qol Medical, LLC | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.61 | 2022 | |
| Jazz Pharmaceuticals INC. | $122.60 | 2022 | |
| Glaxosmithkline, LLC. | $121.48 | 2023 | |
| Idorsia Pharmaceuticals US INC | $117.45 | 2023 | Quviviq |
| Insmed, INC. | $115.70 | 2021 | |
| Exact Sciences Corporation | $91.12 | 2023 | Cologuard Collection Kit |
| Viatris Specialty LLC | $82.28 | 2025 | Yupelri |
| Abbott Laboratories | $48.17 | 2023 | Gallant |
| Cvrx, INC. | $39.80 | 2023 | Barostim Neo System |
| Sanofi Pasteur INC. | $15.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.